Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4823240 | 0.88 | HPGD (0.68) | POLBHPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL134279 | 0.87 | SMN1; SMN2 (0.62) | POLBHPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL27183334 | 0.86 | SMN1; SMN2 (0.65) | POLBHPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL22225675 | 0.85 | HPGD (0.68) | POLBHPGDRECQLSMN1; SMN2LMNA | |
| SCHEMBL856142 | 0.85 | SMN1; SMN2 (0.60) | POLBHPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL8301733 | 0.85 | SMN1; SMN2 (0.60) | POLBHPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL29582937 | 0.84 | POLB (1.00) | POLBHPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL4186439 | 0.84 | POLB (1.00) | POLBHPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL1726857 | 0.83 | LMNA (0.76) | POLBSMN1; SMN2LMNAKMT2ATSHR | |
| SCHEMBL691809 | 0.83 | SMN1; SMN2 (0.59) | POLBHPGDSMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101970420-A | Oxadiazole derivatives | MERCK SERONO SA | 2011-02-09 | — | — | CN | disclosed |
| US-7645786-B2 | 1-aryl-4-cyclopropylpyrazoles with at least one fluorine attached to the cyclopropyl ring; parasiticides; fleas; extended duration of action for at least 28 days | PFIZER INC. (US) | 2010-01-12 | — | — | US | disclosed |
| CN-101600696-A | The arylpyrazole that replaces | PFIZER LTD (GB) | 2009-12-09 | — | — | CN | disclosed |
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-20080176865-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20070149550-A1 | 1-aryl-4-cyclopropylpyrazoles with at least one fluorine attached to the cyclopropyl ring; parasiticides; fleas; extended duration of action for at least 28 days | PFIZER INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-20060211740-A1 | Novel compounds | GLAXO GROUP LIMITED | 2006-09-21 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| WO-2005025557-A1 | AN AGENT FOR PLASMINOGEN-ACTIVATION AND MATRIX METALLOPROTEINASE ASSOCIATED CONDITIONS AND METHODS OF USE | MONASH UNIVERSITY (AU) | 2005-03-24 | — | — | WO | disclosed |
| CN-1418192-A | Pharmaceutical compositions containing azetidine derivatives novel azetidine derivatives and preparation thereof | AVENTIS PHARMA SA (FR) | 2003-05-14 | — | — | CN | disclosed |
| US-6355631-B1 | TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA | AVENTIS PHARMA S.A. (FR) | 2002-03-12 | — | — | US | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176865-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP3A4, CYP3A43, CYP4B1 | POLB 3133/4885HPGD 3011/4885RECQL 4383/4885 |
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | POLB 3576/4885HPGD 242/4885RECQL 2422/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | POLB 3576/4885HPGD 242/4885RECQL 2422/4885 |
| US-20070149550-A1 | 1-aryl-4-cyclopropylpyrazoles with at least one fluorine attached to the cyclopropyl ring; parasiticides; fleas; extended duration of action for at least 28 days | CYP3A43, CYP3A4, CYP2F1 | POLB 2927/4885HPGD 3207/4885RECQL 3683/4885 |
| US-20060211740-A1 | Novel compounds | BACE2, BACE1, PSEN2 | POLB 1607/4885HPGD 3779/4885RECQL 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.